Results 31 to 40 of about 265,496 (312)
Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle +5 more
wiley +1 more source
Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
Multiple myeloma (MM) cure remains elusive despite the availability of newer anti-myeloma agents. Patients with high-risk disease often suffer from early relapse and short survival.
Ehsan Malek +3 more
doaj +1 more source
CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet ...
Oren Pasvolsky +10 more
doaj +1 more source
Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. [PDF]
Mixed allogeneically reconstituted mice (B10 + B10.D2----B10) that specifically accept B10.D2 tail skin allografts were examined for in vivo and in vitro immunocompetence, patterns of hematopoietic repopulation, and in vitro reactivity.
Barbieri, SA +4 more
core
Marked mitigation of transplant vascular sclerosis in FasL(gld) (CD95L) mutant recipients. I. The role of alloantibodies in the development of chronic rejection [PDF]
Background. In the acute rejection of allografts, the interaction between Fas (CD95) and its ligand (FasL; CD95L) has been shown to be involved in mediating apoptotic cell death.
Aitouche, A +7 more
core +1 more source
ABSTRACT Background Gastrointestinal graft‐versus‐host disease (GI GVHD) following hematopoietic stem cell transplant is typically managed with medical therapy, but surgery and angioembolization may be warranted in selected cases with life‐threatening complications.
Gaia Brunetti +12 more
wiley +1 more source
Granulocyte‐colony stimulating factor (G‐CSF) is routinely used for peripheral blood stem cells (PBSC) mobilization in healthy donors for allogeneic hematopoietic stem cell transplantation, with mild, transient adverse effects.
Nihar Desai +5 more
doaj +1 more source
Enhanced Immunomodulation in Inflammatory Environments Favors Human Cardiac Mesenchymal Stromal-Like Cells for Allogeneic Cell Therapies [PDF]
Rising numbers of patients with cardiovascular diseases and limited availability of donor hearts require new and improved therapy strategies. Human atrial appendage-derived cells (hAACs) are promising candidates for an allogeneic cell-based treatment. In
Diedrichs, Falk +5 more
core +1 more source
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider +4 more
wiley +1 more source

